GSK, Galapagos team up on anti-infectives
LONDON In a recent move of acquisitions, GlaxoSmithKline has reached an agreement with Galapagos to discover and develop new anti-infective medicines against up to six targets based on Galapagos’ natural product drug delivery platform, according to Reuters.
Galapagos will receive about $5 million in technology access fees and up to $315 million in total payments for each marketed product. The company will also be responsible for the discovery and development of natural product small molecule drug candidates in clinical trials. After this, GSK will have the option to license each compound for further development and commercialization on a worldwide basis.
The move reflects GSK’s decision to place more emphasis on developing new antibiotics and anti-virals, after announcing in February it was setting up a new drug-discovery unit devoted to infectious diseases.
Some of the recent deals by GSK are: an agreement with OncoMed for the development of novel antibodies believed to be involved with the spread and recurrence of cancer; an agreement with Synta Pharmaceuticals for the rights to its experimental skin cancer drug; a multi-billion brain drug deal with Targacept; and a deal to buy heart drug specialist Reliant Pharmaceuticals for $1.65 billion.
Court overturns $3 million jury award against Wyeth’s Prempro
PHILADELPHIA A judge has overturned a jury’s decision to award a woman $3 million for claiming that Wyeth’s hormone-replacement drug Prempro caused her breast cancer, according to the Associated Press. The judge said the plaintiff did not have sufficient evidence to show that the company acted negligently.
Only four of about 1,500 cases pending in Philadelphia have gone to trial. Each time, a jury sided with the plaintiff only to have the judge reverse the verdict, lawyer Tobi Millrood said. The plaintiff, Jennie Nelson plans on appealing the decision to the state Superior Court.
Nelson had claimed that she was diagnosed in 2001 after taking the drug for five years to treat symptoms of menopause. Her lawyers argued that the manufacturer Wyeth had knowledge the drug caused cancer, yet failed to issue adequate warnings.
This is in contrast to a recent decision in Nevada that saw Wyeth lose a verdict to three women who made the same claims. The women won $134 million in that case.
Sun Pharma, Novartis reach agreement on Exelon
MUMBAI, India Sun Pharmaceuticals and Novartis have reached an out-of-court settlement in relation to Novartis’ Alzheimer’s drug Exelon, according to published reports.
“Under the terms of the settlement, Sun Pharma will not market generic Exelon in the U.S. until sometime prior to the expiration of the patents covering Exelon. The specific date on which Sun may launch and the other terms of the agreement are confidential,” said Sun Pharma in a statement.
Sun Pharma, being one of the first to file an application to sell generic Exelon in the U.S, was eligible to share a 180-day marketing exclusivity on the drug. However, had it launched its generic version of Exelon before reaching an agreement with Novartis, it would have done so at risk of damage claims by Novartis for patent infringement.
Exelon had sales of about $200 million last year in the U.S.